$4.50
4.41% yesterday
Nasdaq, Oct 09, 10:16 pm CET
ISIN
US02155X1063
Symbol
ATHE

Alterity Therapeutics Ltd. Sponsored ADR Stock price

$4.50
-0.52 10.32% 1M
+1.75 63.34% 6M
+1.19 35.95% YTD
+3.19 243.51% 1Y
+0.13 2.86% 3Y
-15.80 77.83% 5Y
-48.12 91.45% 10Y
-79.50 94.64% 20Y
Nasdaq, Closing price Thu, Oct 09 2025
+0.19 4.41%
ISIN
US02155X1063
Symbol
ATHE
Industry

Key metrics

Basic
Market capitalization
$78.4m
Enterprise Value
$56.8m
Net debt
positive
Cash
$21.7m
Shares outstanding
9.1b
Valuation (TTM | estimate)
P/E
- | -
P/S
270.5 | 29.2
EV/Sales
195.9 | 21.2
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-33.5%
ROIC
-152.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$290.0k | $2.7m
EBITDA
$-9.2m | $-13.5m
EBIT
$-9.3m | $-14.7m
Net Income
$-8.0m | $0.0
Free Cash Flow
$-7.5m
Growth (TTM | estimate)
Revenue
61.1% | 825.8%
EBITDA
26.6% | -45.8%
EBIT
26.5% | -57.7%
Net Income
36.5% | 100.0%
Free Cash Flow
9.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,153.8% | -501.2%
EBIT
-3,185.1%
Net
-2,721.9% | 0.0%
Free Cash Flow
-2,565.8%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
0.4%
Employees
10
Rev per Employee
$30.0k
Show more

Is Alterity Therapeutics Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,998 stocks worldwide.

Financial data from Alterity Therapeutics Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.29 0.29
61% 61%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.59 3.59
13% 13%
1,238%
- Research and Development Expense 9.44 9.44
23% 23%
3,255%
-9.23 -9.23
27% 27%
-3,183%
- Depreciation and Amortization 0.09 0.09
10% 10%
31%
EBIT (Operating Income) EBIT -9.32 -9.32
26% 26%
-3,214%
Net Profit -7.96 -7.96
37% 37%
-2,745%

In millions USD.

Don't miss a Thing! We will send you all news about Alterity Therapeutics Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alterity Therapeutics Ltd. Sponsored ADR Stock News

Neutral
GlobeNewsWire
about 20 hours ago
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging and biomarker analysis advance understanding of MSA diagnosis – MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” ...
Neutral
GlobeNewsWire
8 days ago
– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –
Neutral
GlobeNewsWire
about one month ago
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for a capital raising of A$20.0 million (the “Placement”) of fully paid ordinary sh...
More Alterity Therapeutics Ltd. Sponsored ADR News

Company Profile

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Dr. Stamler
Employees 10
Founded 1997
Website alteritytherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today